MINAPHARM Pharmaceuticals Statistics

Total Valuation

MINAPHARM Pharmaceuticals has a market cap or net worth of EGP 1.74 billion. The enterprise value is 4.15 billion.

Market Cap	1.74B
Enterprise Value	4.15B

Important Dates

The next estimated earnings date is Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	May 8, 2024

Share Statistics

MINAPHARM Pharmaceuticals has 11.06 million shares outstanding.

Shares Outstanding	11.06M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.66%
Owned by Institutions (%)	n/a
Float	1.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.44
PB Ratio	0.44
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.73, with an EV/FCF ratio of -6.04.

EV / Earnings	-15.18
EV / Sales	1.06
EV / EBITDA	10.73
EV / EBIT	27.82
EV / FCF	-6.04

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 1.36.

Current Ratio	1.14
Quick Ratio	0.76
Debt / Equity	1.36
Debt / EBITDA	14.39
Debt / FCF	-8.09
Interest Coverage	0.36

Financial Efficiency

Return on equity (ROE) is -5.71% and return on invested capital (ROIC) is 1.14%.

Return on Equity (ROE)	-5.71%
Return on Assets (ROA)	0.97%
Return on Capital (ROIC)	1.14%
Revenue Per Employee	8.70M
Profits Per Employee	-607,082
Employee Count	450
Asset Turnover	0.41
Inventory Turnover	2.43

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.31% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-22.31%
50-Day Moving Average	167.92
200-Day Moving Average	209.40
Relative Strength Index (RSI)	36.42
Average Volume (20 Days)	5,835

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MINAPHARM Pharmaceuticals had revenue of EGP 3.92 billion and -273.19 million in losses. Loss per share was -24.69.

Revenue	3.92B
Gross Profit	1.01B
Operating Income	149.12M
Pretax Income	-260.21M
Net Income	-273.19M
EBITDA	343.18M
EBIT	149.12M
Loss Per Share	-24.69

Full Income Statement

Balance Sheet

The company has 3.26 billion in cash and 5.56 billion in debt, giving a net cash position of -2.30 billion or -207.53 per share.

Cash & Cash Equivalents	3.26B
Total Debt	5.56B
Net Cash	-2.30B
Net Cash Per Share	-207.53
Equity (Book Value)	4.08B
Book Value Per Share	358.70
Working Capital	658.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 234.83 million and capital expenditures -921.86 million, giving a free cash flow of -687.03 million.

Operating Cash Flow	234.83M
Capital Expenditures	-921.86M
Free Cash Flow	-687.03M
FCF Per Share	-62.10

Full Cash Flow Statement

Margins

Gross margin is 25.70%, with operating and profit margins of 3.81% and -6.67%.

Gross Margin	25.70%
Operating Margin	3.81%
Pretax Margin	-6.64%
Profit Margin	-6.67%
EBITDA Margin	8.76%
EBIT Margin	3.81%
FCF Margin	-17.54%

Dividends & Yields

This stock pays an annual dividend of 1.65, which amounts to a dividend yield of 1.05%.

Dividend Per Share	1.65
Dividend Yield	1.05%
Dividend Growth (YoY)	-41.07%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	1.05%
Earnings Yield	-15.73%
FCF Yield	-39.57%

Dividend Details

Stock Splits

The last stock split was on March 19, 2009. It was a forward split with a ratio of 10.

Last Split Date	Mar 19, 2009
Split Type	Forward
Split Ratio	10

Scores

MINAPHARM Pharmaceuticals has an Altman Z-Score of 0.91. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.91
Piotroski F-Score	n/a